Kopp Investment Advisors buys $4,969,639 stake in Omnicell (OMCL)

Omnicell (OMCL) : Kopp Investment Advisors scooped up 9,065 additional shares in Omnicell during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 132,312 shares of Omnicell which is valued at $4,969,639.Omnicell makes up approximately 2.25% of Kopp Investment Advisors’s portfolio.

Other Hedge Funds, Including , Highbridge Capital Management added OMCL to its portfolio by purchasing 10,394 company shares during the most recent quarter which is valued at $390,399. Omnicell makes up approx 0.01% of Highbridge Capital Management’s portfolio.Sentinel Asset Management boosted its stake in OMCL in the latest quarter, The investment management firm added 17,680 additional shares and now holds a total of 344,380 shares of Omnicell which is valued at $12,934,913. Omnicell makes up approx 0.29% of Sentinel Asset Management’s portfolio.Oppenheimerfunds boosted its stake in OMCL in the latest quarter, The investment management firm added 183,310 additional shares and now holds a total of 418,257 shares of Omnicell which is valued at $15,709,733. Omnicell makes up approx 0.02% of Oppenheimerfunds’s portfolio.Alliancebernstein boosted its stake in OMCL in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 58,846 shares of Omnicell which is valued at $2,210,256. Globeflex Capital L P sold out all of its stake in OMCL during the most recent quarter. The investment firm sold 20 shares of OMCL which is valued $751.

Omnicell opened for trading at $37.68 and hit $38.34 on the upside on Thursday, eventually ending the session at $38.3, with a gain of 1.92% or 0.72 points. The heightened volatility saw the trading volume jump to 1,62,464 shares. Company has a market cap of $1,385 M.

On the company’s financial health, Omnicell reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.32. The company had revenue of $175.60 million for the quarter, compared to analysts expectations of $170.88 million. The company’s revenue was up 55.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 EPS.

Many Wall Street Analysts have commented on Omnicell. Company shares were Reiterated by FBR Capital on Jul 7, 2016 to “Outperform”, Firm has raised the Price Target to $ 40 from a previous price target of $35 .

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.